PL310373A1 - Compounds of pharmaceutic activity, method of obtaining them and pharmaceutic composition - Google Patents
Compounds of pharmaceutic activity, method of obtaining them and pharmaceutic compositionInfo
- Publication number
- PL310373A1 PL310373A1 PL95310373A PL31037395A PL310373A1 PL 310373 A1 PL310373 A1 PL 310373A1 PL 95310373 A PL95310373 A PL 95310373A PL 31037395 A PL31037395 A PL 31037395A PL 310373 A1 PL310373 A1 PL 310373A1
- Authority
- PL
- Poland
- Prior art keywords
- optionally substituted
- alkyl
- pharmaceutic
- hydrogen
- substituted phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Holo Graphy (AREA)
- Gyroscopes (AREA)
- Optical Integrated Circuits (AREA)
Abstract
A pharmaceutical compound of the formula <CHEM> in which R<1> and R<7> are each halo, trifluoromethyl, C1-6 alkyl, C1-6 alkoxy, optionally substituted phenyl, optionally substituted naphthyl or optionally substituted heteroaryl, R<2> and R<3> are each hydrogen or C1-6 alkyl, R<4> and R<5> are each hydrogen, halo, trifluoromethyl, C1-6 alkyl, C1-6 alkoxy, optionally substituted phenyl, optionally substituted naphthyl or optionally substituted heteroaryl, R<6> is hydrogen, C1-6 alkyl, optionally substituted phenyl, optionally substituted naphthyl, optionally substituted heteroaryl, optionally substituted phenyl-C1-6 alkyl or -CO2R<8> where R<8> is an ester group, m and p are each 0, 1, 2, 3 or 4, n is 1, 2, 3 or 4, Z is <CHEM> where R<9> and R<1><0> are each hydrogen, C1-6 alkyl or optionally substituted phenyl-C1-6 alkyl, X is oxygen or sulphur, and Y is <CHEM> where R<1><1> and R<1><2> are each hydrogen, C1-6 alkyl, trifluoromethyl, optionally substituted phenyl, optionally substituted naphthyl or optionally substituted heteroaryl; and salts and solvates thereof. The compounds of the invention are indicated for use in the treatment of diseases of the central nervous system. They are active in tests that indicate serotonergic modulation.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9418326A GB9418326D0 (en) | 1994-09-12 | 1994-09-12 | Pharmaceutical compounds |
GBGB9511166.2A GB9511166D0 (en) | 1995-06-02 | 1995-06-02 | Pharmaceutical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
PL310373A1 true PL310373A1 (en) | 1996-03-18 |
Family
ID=26305611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL95310373A PL310373A1 (en) | 1994-09-12 | 1995-09-11 | Compounds of pharmaceutic activity, method of obtaining them and pharmaceutic composition |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP0705832B1 (en) |
JP (1) | JPH0881464A (en) |
KR (1) | KR960010635A (en) |
CN (1) | CN1045602C (en) |
AT (1) | ATE247114T1 (en) |
AU (1) | AU698580B2 (en) |
CA (1) | CA2157998A1 (en) |
CZ (1) | CZ286565B6 (en) |
DE (1) | DE69531476T2 (en) |
ES (1) | ES2204932T3 (en) |
FI (1) | FI954243A (en) |
HU (1) | HU219491B (en) |
IL (1) | IL115236A (en) |
IN (1) | IN179550B (en) |
MY (1) | MY132009A (en) |
NO (1) | NO305174B1 (en) |
NZ (1) | NZ272961A (en) |
PE (1) | PE41796A1 (en) |
PH (1) | PH31631A (en) |
PL (1) | PL310373A1 (en) |
RU (1) | RU2146256C1 (en) |
TR (1) | TR199501114A2 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2308362A (en) * | 1995-12-19 | 1997-06-25 | Lilly Industries Ltd | Pharmaceutical indole derivatives |
EP0905136A1 (en) * | 1997-09-08 | 1999-03-31 | Janssen Pharmaceutica N.V. | Tetrahydro gamma-carbolines |
UA70334C2 (en) * | 1998-10-06 | 2004-10-15 | Janssen Pharmaceutica N V Jans | BENZOTHIENO[3,2-c]PYRIDINES AS a2 ANTAGONISTS BENZOTHIENO[3,2-c]PYRIDINES AS a2 ANTAGONISTS |
UA74826C2 (en) * | 2000-05-17 | 2006-02-15 | Ortho Mcneil Pharm Inc | ?-carboline derivatives as phosphodiesterase inhibitors |
EP1303502A2 (en) * | 2000-07-06 | 2003-04-23 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Tetrahydrobenzothiazole analogues as neuroprotective agents |
DE10040016A1 (en) * | 2000-08-16 | 2002-02-28 | Boehringer Ingelheim Pharma | Novel beta-amyloid inhibitors, process for their preparation and their use as pharmaceuticals |
US6586435B2 (en) | 2000-09-19 | 2003-07-01 | Boehringer Ingelheim Pharma Kg | Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors |
CA2417082C (en) * | 2000-09-19 | 2009-11-17 | Enzo Cereda | New benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors |
EP1322622B1 (en) * | 2000-09-19 | 2012-10-31 | Sprout Pharmaceuticals, Inc. | New n, n'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors |
US7183410B2 (en) | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
JP2005526691A (en) | 2001-08-08 | 2005-09-08 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | Therapeutic agent 1H-pyrido [4,3-b] indole |
US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
JP2009503020A (en) | 2005-08-03 | 2009-01-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Use of flibanserin in the treatment of obesity |
WO2007048803A1 (en) | 2005-10-29 | 2007-05-03 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
EP2037927B1 (en) | 2006-06-30 | 2010-01-27 | Boehringer Ingelheim International GmbH | Flibanserin for the treatment of urinary incontinence and related diseases |
CL2007002214A1 (en) | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | PHARMACEUTICAL COMPOSITION IN THE FORM OF COMPRESSED, WHERE AT LEAST THE LENGTH OF THE COMPRESSED IN THE PREVIOUS STATE OF THE APPLICATION IS AT LEAST 7/12 OF THE PILOR DIAMETER OF THE PATIENT AND AFTER INGERING IT IN THE FOOD STATE, THE LENGTH OF THE COMP |
EA200900264A1 (en) | 2006-08-14 | 2009-08-28 | Бёрингер Ингельхайм Интернациональ Гмбх | COMPOSITIONS OF FLIBANSERIN AND METHOD OF THEIR PREPARATION |
EA200900270A1 (en) | 2006-08-25 | 2009-08-28 | Бёрингер Ингельхайм Интернациональ Гмбх | SYSTEMS OF ADJUSTABLE GRINDING AND METHOD OF THEIR PREPARATION |
UY31335A1 (en) | 2007-09-12 | 2009-04-30 | VASOMOTOR SYMPTOMS TREATMENT | |
AU2010253336A1 (en) * | 2009-05-29 | 2011-12-08 | Sumitomo Chemical Company, Limited | Agent for treatment or prevention of diseases associated with activity of neurotrophic factors |
SI3355884T1 (en) | 2015-10-01 | 2021-11-30 | Olema Pharmaceuticals, Inc. | TETRAHYDRO-1H-PYRIDO(3,4-b)INDOLE ANTI-ESTROGENIC DRUGS |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4035369A (en) | 1975-10-08 | 1977-07-12 | Janssen Pharmaceutica N.V. | 1-Benzazolylalkyl-4-substituted-piperidines |
IL69132A (en) * | 1982-07-14 | 1986-02-28 | Roussel Uclaf | Benzo-and naphtho-thiopyranopyrimidinones,their preparation and pharmaceutical compositions containing them |
FR2661177A1 (en) * | 1990-04-23 | 1991-10-25 | Rhone Poulenc Sante | DERIVATIVES OF NAPHTOSULTAM ANTAGONISTS OF SEROTONIN, THEIR PREPARATION AND THE MEDICINES CONTAINING THEM |
-
1995
- 1995-09-07 EP EP95306253A patent/EP0705832B1/en not_active Expired - Lifetime
- 1995-09-07 DE DE69531476T patent/DE69531476T2/en not_active Expired - Fee Related
- 1995-09-07 AT AT95306253T patent/ATE247114T1/en not_active IP Right Cessation
- 1995-09-07 ES ES95306253T patent/ES2204932T3/en not_active Expired - Lifetime
- 1995-09-08 PH PH51266A patent/PH31631A/en unknown
- 1995-09-08 HU HU9502631A patent/HU219491B/en not_active IP Right Cessation
- 1995-09-08 AU AU30497/95A patent/AU698580B2/en not_active Ceased
- 1995-09-08 CZ CZ19952322A patent/CZ286565B6/en not_active IP Right Cessation
- 1995-09-08 MY MYPI95002675A patent/MY132009A/en unknown
- 1995-09-08 NZ NZ272961A patent/NZ272961A/en unknown
- 1995-09-11 KR KR1019950029475A patent/KR960010635A/en not_active Application Discontinuation
- 1995-09-11 JP JP7231873A patent/JPH0881464A/en active Pending
- 1995-09-11 PL PL95310373A patent/PL310373A1/en unknown
- 1995-09-11 IN IN1079CA1995 patent/IN179550B/en unknown
- 1995-09-11 CN CN95117133A patent/CN1045602C/en not_active Expired - Fee Related
- 1995-09-11 RU RU95115522A patent/RU2146256C1/en active
- 1995-09-11 FI FI954243A patent/FI954243A/en unknown
- 1995-09-11 NO NO953575A patent/NO305174B1/en not_active IP Right Cessation
- 1995-09-11 IL IL115236A patent/IL115236A/en not_active IP Right Cessation
- 1995-09-11 CA CA002157998A patent/CA2157998A1/en not_active Abandoned
- 1995-09-12 TR TR95/01114A patent/TR199501114A2/en unknown
- 1995-09-12 PE PE1995278830A patent/PE41796A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
FI954243A (en) | 1996-03-13 |
RU2146256C1 (en) | 2000-03-10 |
KR960010635A (en) | 1996-04-20 |
CZ286565B6 (en) | 2000-05-17 |
CN1045602C (en) | 1999-10-13 |
IN179550B (en) | 1997-10-18 |
ES2204932T3 (en) | 2004-05-01 |
ATE247114T1 (en) | 2003-08-15 |
NO953575D0 (en) | 1995-09-11 |
IL115236A0 (en) | 1995-12-31 |
IL115236A (en) | 1998-06-15 |
PE41796A1 (en) | 1996-10-21 |
CZ232295A3 (en) | 1996-03-13 |
NO305174B1 (en) | 1999-04-12 |
NZ272961A (en) | 1998-02-26 |
AU3049795A (en) | 1996-03-28 |
CA2157998A1 (en) | 1996-03-13 |
DE69531476D1 (en) | 2003-09-18 |
NO953575L (en) | 1996-03-13 |
FI954243A0 (en) | 1995-09-11 |
HUT72593A (en) | 1996-05-28 |
JPH0881464A (en) | 1996-03-26 |
CN1129219A (en) | 1996-08-21 |
EP0705832B1 (en) | 2003-08-13 |
TR199501114A2 (en) | 1996-10-21 |
HU219491B (en) | 2001-04-28 |
EP0705832A1 (en) | 1996-04-10 |
MY132009A (en) | 2007-09-28 |
DE69531476T2 (en) | 2004-06-09 |
PH31631A (en) | 1999-01-12 |
AU698580B2 (en) | 1998-11-05 |
HU9502631D0 (en) | 1995-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL310373A1 (en) | Compounds of pharmaceutic activity, method of obtaining them and pharmaceutic composition | |
AU3113793A (en) | Intermediates for preparing antipicornaviral pyridazinamines | |
IL108091A0 (en) | Inhibitors of hiv protease useful for the treatment of aids | |
DE69707372D1 (en) | Use of a phosphoric acid diester for the manufacture of a medicament for the treatment of acne | |
ATE122042T1 (en) | PYRAZOLOISOQUINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME. | |
DE69706386D1 (en) | 2-aryl-3-aminoaryloxynaphthyl compounds, intermediates, compositions and methods | |
DE59607208D1 (en) | Use of a sodium or lysinium salt of crotonic acid amide derivatives for the manufacture of a medicament for the treatment of cancer | |
ES2183036T3 (en) | 2,2 '- DISUSTITUIDOS-FERROCENOS 2,2`-DISUSTITUIDOS and 1-PHOSPHINO-FERROCENOS 1`, 2-DISUSTITUIDOS, PROCEDURE FOR THEIR PREPARATION, ITS USE, AS WELL AS COMPLEXES OF TRANSITION METALS CONTAINING THEM. | |
NZ316516A (en) | quinoline substituted carbamoyl carboxylic acid amides and medicaments | |
SU1568881A3 (en) | Method of fighting diseases of plants | |
ATE267832T1 (en) | SUBSTANCE GM-95, METHOD FOR PRODUCTION THEREOF AND USE THEREOF | |
GR3000904T3 (en) | Amide derivatives | |
ATE281452T1 (en) | 4-AMINO-2-UREIDO-PYRIMIDINE-5-CARBONIC ACID AMIDES, METHOD FOR THE PRODUCTION THEREOF, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND THEIR USE | |
DE69711506D1 (en) | Methylsulfomycin 1, process for its preparation and use | |
ATE186912T1 (en) | CARBAMOYLPYRROLIDONE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AND CEREBROVASCULAR DISORDERS | |
ES8707939A1 (en) | N-carboxyalcoyl-2-oxo-3-diaryl-5,6-triazines useful as therapeutic agents. | |
NO972942D0 (en) | 4-Amino-2-ureido-pyrimidine-5-carboxylic acid amides, processes for their preparation, drugs containing these compounds and their use | |
AU7932100A (en) | N-substituted 3-amino-2,2-di-c-alkyl-1,4-butyrolactones and 1,4-thiobutyrolactones for use as promoter of gamma-aminobutyric acid activity and for treating nervous disorders and preparation method |